- Home
- GAME vs LPCN Comparison
GAME vs LPCN Comparison
Compare GAME & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- LPCN
- Stock Information
- Founded
- GAME 2011
- LPCN 1997
- Country
- GAME United States
- LPCN United States
- Employees
- GAME N/A
- LPCN N/A
- Industry
- GAME
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- LPCN Health Care
- Exchange
- GAME Nasdaq
- LPCN Nasdaq
- Market Cap
- GAME 25.8M
- LPCN 16.4M
- IPO Year
- GAME 2009
- LPCN N/A
- Fundamental
- Price
- GAME $0.69
- LPCN $3.30
- Analyst Decision
- GAME Strong Buy
- LPCN Strong Buy
- Analyst Count
- GAME 3
- LPCN 1
- Target Price
- GAME $3.67
- LPCN $10.00
- AVG Volume (30 Days)
- GAME 303.6K
- LPCN 15.2K
- Earning Date
- GAME 04-15-2025
- LPCN 05-08-2025
- Dividend Yield
- GAME N/A
- LPCN N/A
- EPS Growth
- GAME N/A
- LPCN N/A
- EPS
- GAME N/A
- LPCN N/A
- Revenue
- GAME $99,072,646.00
- LPCN $7,922,926.00
- Revenue This Year
- GAME $102.01
- LPCN N/A
- Revenue Next Year
- GAME $17.88
- LPCN N/A
- P/E Ratio
- GAME N/A
- LPCN N/A
- Revenue Growth
- GAME 210.51
- LPCN N/A
- 52 Week Low
- GAME $0.60
- LPCN $2.91
- 52 Week High
- GAME $2.25
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- GAME 40.22
- LPCN 43.33
- Support Level
- GAME $0.60
- LPCN $2.96
- Resistance Level
- GAME $0.72
- LPCN $3.62
- Average True Range (ATR)
- GAME 0.09
- LPCN 0.26
- MACD
- GAME -0.01
- LPCN 0.05
- Stochastic Oscillator
- GAME 28.47
- LPCN 54.78
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.